Rationale Therapie der Parkinsonerkrankung mit Dopaminagonisten

Abstract

Idiopathic Parkinson's disease is one of the most frequent neurological diseases. Besides L-dopa dopamine agonists play a major role in therapy of this condition. In most guidelines it is advocated to use dopamine agonists proferentially in monotherapy or in combination in de novo patients younger than 70 years old. To avoid dyskinesias continuous dopamine receptor stimulation should be achieved. This may be very well accomplished by the use of a transdermally applicated dopamine agonist which results in constant plasma levels over the whole day.